Eris Lifesciences · NSE: ERIS · BSE: 540596
Q2 FY22 results · Jul–Sep 2021
Eris Lifesciences reported revenue from operations of ₹359.67 crore (up 9.0% from Q2 FY21) and net profit of ₹118.39 crore (up 9.9% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 359.67 | 329.99 | +9.0% | 349.27 | +3.0% |
| Other income | 6.99 | 2.08 | +235.3% | 5.87 | +19.1% |
| Total income | 366.66 | 332.08 | +10.4% | 355.13 | +3.2% |
| Profit before tax | 130.78 | 115.84 | +12.9% | 117.10 | +11.7% |
| Net profit for the period | 118.39 | 107.72 | +9.9% | 106.66 | +11.0% |
| EPS, basic (₹) | 8.71 | 7.93 | +9.8% | 7.86 | +10.8% |
| Net margin (%) | 32.9 | 32.6 | 30.5 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 322.66 | 303.37 | +6.4% | 306.30 | +5.3% |
| Other income | 7.65 | 2.41 | +217.6% | 6.45 | +18.7% |
| Total income | 330.31 | 305.78 | +8.0% | 312.74 | +5.6% |
| Profit before tax | 132.29 | 112.94 | +17.1% | 117.30 | +12.8% |
| Net profit for the period | 119.71 | 105.49 | +13.5% | 106.72 | +12.2% |
| EPS, basic (₹) | 8.81 | 7.77 | +13.4% | 7.86 | +12.1% |
| Net margin (%) | 37.1 | 34.8 | 34.8 |
Consolidated
- Filed with BSE
- 30 Oct 2021, 14:51 IST
- Board meeting
- 29 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Oct 2021, 14:51 IST
- Board meeting
- 29 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE